Navigation Links
Viral infections, including flu, could be inhibited by naturally occurring protein

PITTSBURGH, June 12, 2014 By boosting a protein that naturally exists in our cells, an international team of researchers led by the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter, has found a potential way to enhance our ability to sense and inhibit viral infections.

The laboratory-based discovery, which could lead to more effective treatments for viruses ranging from hepatitis C to the flu, appears in the June 19 issue of the journal Immunity. The research is supported by the National Institutes of Health.

"Despite remarkable advances in vaccination and treatment, diseases caused by viral infections remain among the leading causes of death worldwide," said senior author Saumendra N. Sarkar, Ph.D., assistant professor of microbiology and molecular genetics at UPCI. "We need new defenses against viral infections, and our discovery is proving to be a promising avenue for further exploration."

Dr. Sarkar and his team made the discovery while investigating a protein called oligoadenylate synthetases-like, or OASL, which appears in increased quantities in people with liver cancer caused by the hepatitis C virus.

Hepatitis C, influenza, the childhood respiratory illness RSV, and many other viruses are known as ribonucleic acid (RNA) viruses, which use RNA as their genetic material when they replicate. The OASL protein enhances cells' ability to detect virus RNA, activating the immune system to sense the virus and inhibit replication.

In laboratory tests, boosting this protein in human cells effectively inhibits viral replication. Conversely, mice that do not have OASL were found to be much more susceptible to viral infections.

The finding is especially notable because it may offer an alternative to interferons, another kind of protein that is made and released by cells in response to viruses. Interferons are used in therapy against some viral infections, including hepatitis C, but are not effective for other RNA viruses, such as influenza. Interferon therapy also has major side effects, and not all patients respond well to treatment.

Dr. Sarkar and his team plan to determine the most efficient way to boost the OASL pathway in patients and are working with pulmonologists to develop and identify funding for a study to evaluate the effect of boosting OASL in people with lung infections.

"The respiratory system is a much easier target to deliver this type of therapy, compared to an organ, such as the liver, so we'll be starting with infections like RSV," said Dr. Sarkar. "From there we could branch out to other RNA viruses and perhaps find effective ways to boost our inherent immunity against a broad range of viral infections."


Contact: Allison Hydzik
University of Pittsburgh Schools of the Health Sciences

Related medicine news :

1. Antiviral therapy may prevent liver cancer in hepatitis B patients
2. Our own treacherous immune genes can cause cancer after viral infection
3. Hemorrhagic fevers can be caused by bodys antiviral interferon response
4. Going viral to target tumors
5. Could statins be used to fight a deadly viral infection?
6. Long distance signals protect brain from viral infections
7. Viral microRNAs responsible for causing AIDS-related cancer, new USC study shows
8. Does the bodys immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?
9. Population Council awarded USAID cooperative agreement to develop non-antiretroviral HIV microbicide
10. PDL-1 antibody could help immune system fight off influenza viral infection, study suggests
11. BU researchers explore possible link between cognitive depressive symptoms and antiretroviral therapy uptake
Post Your Comments:
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government ... ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies and ... opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... encouraging people across the country to celebrate their sobriety and show through pictures ... post “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude on their ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of Botto ... by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented ... IL App (2d) 130884WC. , According to court documents, Adcock testified that on May ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... - Will Also Offer Point ... (CME) --> - Will Also Offer ... (CME) --> - Will ... Education (CME) Elsevier , a world-leading ... feature latest diagnostic imaging textbooks and decision support tools, as well ...
(Date:11/25/2015)... --> --> ... für das Patent über eine neue Hepatitis-B-Behandlung, welches sie ... an Enyo Pharma vergeben haben. Im Rahmen ... und von Edelris gemeinsam mit seinen Partnern Inserm und ... HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die ...
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
Breaking Medicine Technology: